| dc.description.abstract | Introduction: Sepsis is a life-threatening condition of organ dysfunction caused by dysregulation of the host's response to infection. Albumin levels in the blood are an indicator for assessing the severity of sepsis. In sepsis patients, administering albumin extract from Channa striata has better potential in replacing Human Albumin 20%. Based on this, the author wants to see the role of administering Channa striata extract (CSE) in improving albumin and creatinine in sepsis patients.
Method: This research is a quasi-experimental research, withpre-post-test designWhichheldin the ICU at the Haji Adam Malik Central General Hospital, Medan.The research was conducted from July to September 2023 and has passed the Institutional Review Board from the Health Research Ethics Committee Universitas Sumatera Utara. Sepsis patients who meet the inclusion and exclusion criteria and signed the informed consent will be divided into two groups, treatment and control. Both of the group received the same therapy protocol, except for the treatment group will be given CSE at a dose of 5gr, 3 times a day, for 5 days. Measurements of albumin, creatinine, and SOFA score will be taken before the treatment and on the 7th day. All data will be tabulated and analyzed using statistical software.
Results: This study consisted of 2 groups, with a sample size of 20 patients for each group. It was found that the mean age of the research sample was 56.1 + 11.8 years. In the treatment group there was no decrease in albumin levels before and after (2.76 + 0.41 to 2.76 + 0.40), p=0.952. In assessing creatinine levels, there was no significant difference before and after treatment, p>0.05. There was an increase in in SOFA score before and after treatment in both groups, p<0.05.
Conclusion: The use of CSE is clinically significant in improving sepsis patients in the ICU. | en_US |
